(Q50603809)

16 March 2018

title

An epidemiologic analysis of end-stage lupus nephritis. (English)

1 reference

16 March 2018

author name string

Iseki K

1

1 reference

16 March 2018

Miyasato F

2

1 reference

16 March 2018

Oura T

3

1 reference

16 March 2018

Uehara H

4

1 reference

16 March 2018

Nishime K

5

1 reference

16 March 2018

Fukiyama K

6

1 reference

16 March 2018

publication date

1 April 1994

1 reference

16 March 2018

American Journal of Kidney Diseases

published in

1 reference

16 March 2018

volume

23

1 reference

16 March 2018

issue

4

1 reference

16 March 2018

page(s)

547-554

1 reference

16 March 2018

Dialysis and transplantation in patients with renal failure due to systemic lupus erythematosus. The Australian and New Zealand experience

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Survival rates of 2,728 patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

End-stage renal disease in Michigan. Incidence, underlying causes, prevalence, and modalities of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Survival analysis of dialysis patients in Okinawa, Japan (1971-1990).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Reversible “end-stage” lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Epidemiologic approach to the etiology of type I diabetes mellitus and its complications

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Declining incidence of persistent proteinuria in type I (insulin-dependent) diabetic patients in Denmark

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Why do patients with lupus nephritis die?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Application, to Japanese patients, of the 1982 American Rheumatism Association revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Stroke in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Accelerated atherosclerosis in prolonged maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

The role of hypertension in hemodialysis-associated atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

The treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Active lupus in a patient receiving long-term hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Membranous Nephropathy: Its Relative Benignity in Women

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Idiopathic membranous nephropathy: The natural history of untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

The clinical course of end-stage renal disease in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Serum albumin is a strong predictor of death in chronic dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980377-5

7 January 2021

10.1016/S0272-6386(12)80377-5

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018